Table 2.

Progression-free and overall survival Cox regression analyses

Covariate	Univariate analysis		Multivariate analysis
	HR (95% CI)	P value	HR (95% CI)	P value
Progression-free survival
Age (continuous variable)	1.01 (1.00 to 1.03)	0.07	1.01 (0.99 to 1.03)	0.26
Male gender	1.14 (0.83 to 1.57)	0.43	1.32 (0.94 to 1.86)	0.11
Non-Hispanic white race/ethnicity	1.03 (0.71 to 1.50)	0.88	1.11 (0.76 to 1.63)	0.59
Cancer type
NSCLC	1.02 (0.72 to 1.45)	0.91	1.13 (0.77 to 1.66)	0.54
Melanoma	0.37 (0.21 to 0.67)	<0.001	0.39 (0.22 to 0.72)	0.002
Anti-CTLA4 administered	1.11 (0.69 to 1.42)	0.66	1.80 (1.02 to 3.19)	0.04
Concurrent/sequential therapy	1.24 (0.89 to 1.74)	0.21	1.13 (0.79 to 1.62)	0.51
BMI≥25	0.69 (0.51 to 0.94)	0.02	0.87 (0.59 to 1.28)	0.48
Weight-based dose ICI	0.96 (0.68 to 1.34)	0.79	1.39 (0.80 to 2.42)	0.24
BMI≥25/Weight-based dose interaction	NA	NA	0.53 (0.26 to 1.10)	0.09
Overall survival
Age (continuous variable)	1.02 (1.01 to 1.04)	0.004	1.02 (1.00 to 1.03)	0.03
Male gender	1.19 (0.88 to 1.62)	0.26	1.41 (1.01 to 1.97)	0.04
Non-Hispanic white race/ethnicity	1.20 (0.83 to 1.72)	0.33	1.34 (0.92 to 1.97)	0.13
Cancer type
NSCLC	1.26 (0.89 to 1.79)	0.19	1.26 (0.86 to 1.85)	0.24
Melanoma	0.47 (0.27 to 0.81)	0.007	0.43 (0.24 to 0.77)	0.004
Anti-CTLA4 administered	1.00 (0.64 to 1.57)	0.99	1.70 (1.01 to 2.88)	0.05
Concurrent/sequential therapy	1.16 (0.82 to 1.62)	0.41	1.09 (0.76 to 1.57)	0.64
BMI≥25	0.77 (0.57 to 1.04)	0.08	0.96 (0.65 to 1.42)	0.85
Weight-based dose ICI	1.04 (0.75 to 1.44)	0.81	1.57 (0.93 to 2.64)	0.09
BMI≥25/Weight-based dose interaction	NA	NA	0.5 (0.25 to 0.99)	0.05

BMI, body mass index; CTLA4, cytotoxic T lymphocyte antigen 4; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; NSCLC, non-small cell lung cancer.